DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024
DBV Technologies (Nasdaq: DBVT), a clinical-stage biopharmaceutical company, has announced it will host a conference call and live audio webcast on Tuesday, July 30th, at 5:30 p.m. ET to discuss its second quarter 2024 financial results and provide a business update. Interested participants can join the call via teleconference or access the live webcast on the company's website. The event details are as follows:
- Teleconference numbers:
United States: +1-877-346-6112
International: +1-848-280-6350
- Webcast: Available on the Investors & Media section of DBV's website
A replay of the presentation will be accessible on the company's website after the event.
DBV Technologies (Nasdaq: DBVT), un'azienda biofarmaceutica in fase clinica, ha annunciato che terrà una conference call e una diretta audio in streaming martedì 30 luglio alle 17:30 ET per discutere i risultati finanziari del secondo trimestre 2024 e fornire un aggiornamento sull'andamento dell'azienda. I partecipanti interessati possono unirsi alla chiamata tramite teleconferenza o accedere alla diretta streaming sul sito web dell'azienda. I dettagli dell'evento sono i seguenti:
- Numeri per la teleconferenza:
Stati Uniti: +1-877-346-6112
Internazionale: +1-848-280-6350
- Streaming: Disponibile nella sezione Investitori e Media del sito di DBV
Una registrazione della presentazione sarà accessibile sul sito dell'azienda dopo l'evento.
DBV Technologies (Nasdaq: DBVT), una empresa biofarmacéutica en etapa clínica, ha anunciado que llevará a cabo una conferencia telefónica y una transmisión en vivo por audio el martes 30 de julio a las 5:30 p.m. ET para discutir sus resultados financieros del segundo trimestre de 2024 y ofrecer una actualización del negocio. Los participantes interesados pueden unirse a la llamada a través de teleconferencia o acceder a la transmisión en vivo en el sitio web de la empresa. Los detalles del evento son los siguientes:
- Números de teleconferencia:
Estados Unidos: +1-877-346-6112
Internacional: +1-848-280-6350
- Transmisión: Disponible en la sección de Inversores y Medios del sitio de DBV
Una grabación de la presentación estará accesible en el sitio web de la empresa después del evento.
DBV 기술(Nasdaq: DBVT), 임상 단계의 생물제약 회사가 2024년 2분기 재무 결과와 사업 업데이트를 논의하기 위해 7월 30일 화요일 오후 5:30 ET에 컨퍼런스 콜 및 실시간 오디오 웹캐스트를 개최한다고 발표했습니다. 관심 있는 참가자들은 전화 회의를 통해 콜에 참여하거나 회사 웹사이트에서 실시간 웹캐스트에 접속할 수 있습니다. 이벤트 세부 사항은 다음과 같습니다:
- 전화 회의 번호:
미국: +1-877-346-6112
국제: +1-848-280-6350
- 웹캐스트: DBV 웹사이트의 투자자 및 미디어 섹션에서 제공됩니다.
행사 후 회사 웹사이트에서 발표의 녹취록을 열람할 수 있습니다.
DBV Technologies (Nasdaq: DBVT), une entreprise biopharmaceutique en phase clinique, a annoncé qu'elle organisera une conférence téléphonique et un webinaire audio en direct le mardi 30 juillet à 17h30 ET pour discuter de ses résultats financiers du deuxième trimestre 2024 et fournir une mise à jour sur l'entreprise. Les participants intéressés peuvent rejoindre l'appel par téléconférence ou accéder au webinaire en direct sur le site Web de l'entreprise. Les détails de l'événement sont les suivants :
- Numéros de téléconférence :
États-Unis : +1-877-346-6112
International : +1-848-280-6350
- Webinaire : Disponible dans la section Investisseurs & Médias du site de DBV
Une rediffusion de la présentation sera accessible sur le site de l'entreprise après l'événement.
DBV Technologies (Nasdaq: DBVT), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat angekündigt, dass es am Dienstag, den 30. Juli um 17:30 Uhr ET eine Telefonkonferenz und ein Live-Audio-Webcast abhalten wird, um die Finanzergebnisse des zweiten Quartals 2024 zu erörtern und ein Update zum Unternehmen zu geben. Interessierte Teilnehmer können sich über Telekonferenz einwählen oder den Live-Webcast auf der Website des Unternehmens abrufen. Die Einzelheiten der Veranstaltung sind wie folgt:
- Telefonnummern für die Telekonferenz:
Vereinigte Staaten: +1-877-346-6112
International: +1-848-280-6350
- Webcast: Verfügbar im Bereich Investoren & Medien auf der Website von DBV
Eine Wiederholung der Präsentation wird nach der Veranstaltung auf der Website des Unternehmens zugänglich sein.
- None.
- None.
Châtillon, France, July 29, 2024
DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, July 30th, at 5:30 p.m. ET to review its second quarter 2024 financial results and provide a business update.
Interested participants may access this call via the below teleconferencing numbers and asking to join the DBV Technologies call:
United States: +1-877-346-6112
International: +1-848-280-6350
A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Viaskin and EPIT are trademarks of DBV Technologies.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com
Media Contact
Angela Marcucci
DBV Technologies
angela.marcucci@dbv-technologies.com
Attachment
FAQ
When will DBV Technologies (DBVT) report its Q2 2024 financial results?
How can investors access DBV Technologies' (DBVT) Q2 2024 earnings call?
Will there be a replay available for DBV Technologies' (DBVT) Q2 2024 earnings presentation?
